Bad news for Guidant as damages to Johnson & Johnson are confirmed
This article was originally published in Clinica
Executive Summary
A US arbitration panel has upheld the preliminary finding it announced in June ordering Guidant to pay Johnson & Johnson's Cordis subsidiary $425m for infringing the latter's Palmaz-Schatz stent patents.